Company profile
REGENERON PHARMACEUTICALS, INC.
NASDAQ:REGNBiotechnology: Pharmaceutical Preparations
Drug pipeline (52)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DUPIXENT | approved | — | 75 | approved |
| DUPIXENT | approved | — | 75 | approved |
| EVKEEZA | approved | — | 0 | — |
| EYLEA | approved | — | 28 | approved |
| EYLEA | approved | — | 28 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (359)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06452771 | phase1 | active_not_recruiting | 2024-06-27 | 2026-12-04 | Regeneron Pharmaceuticals | A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults |
| NCT07526116 | phase1 | recruiting | 2026-06-05 | 2027-02-08 | Regeneron Pharmaceuticals | A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults |
| NCT06413680 | phase1_2 | recruiting | 2024-09-23 | 2030-02-03 | Regeneron Pharmaceuticals | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body |
| NCT07187401 | phase1_2 | recruiting | 2026-02-11 | 2029-11-29 | Regeneron Pharmaceuticals | A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor |
| NCT00871559 | phase1 | completed | 2009-06-01 | 2014-02-01 | Regeneron Pharmaceuticals | A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies |
FDA applications (11)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761508 | 2026-08-19 | BLA | REGENERON PHARMACEUTICALS, INC. | |||||
Loading… | ||||||||
| BLA 125874 | 2026-04-23 | BLA | REGENERON PHARMACEUTICALS, INC. | |||||
Loading… | ||||||||
| BLA 761400 | 2025-07-02 | BLA | REGENERON PHARMACEUTICALS, INC. | |||||
Loading… | ||||||||
| BLA 761339 | 2023-08-18 | BLA | REGENERON PHARMACEUTICALS, INC. | |||||
Loading… | ||||||||
| BLA 761355 | 2023-08-18 | BLA | REGENERON PHARMACEUTICALS, INC. | |||||
Loading… | ||||||||